DRL's many pluses negated by regulatory hit

The operating margin of 27% has been above the company's long term guidance of 25%. However, the good performance was dented after the company disclosed being issued Form 483 containing eight observations from US drug regulator USFDA for two of its facilities at Duvvada in Andhra Pradesh. After surging over 5% following the results, the DRL stock finally closed at a gain of 2%.

https://ift.tt/3w1lWj1